Collegium Pharmaceutical Inc (COLL) Stock AnalysisCOLLCollegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Collegium Pharmaceutical Inc is a good buy right now due to its current price of $23.19, which offers significant upside potential with analyst price targets suggesting increases of 118.76% to $49.83. The company has demonstrated strong profitability with a gross margin of 61.70% in Q3 2025 and a forward P/E ratio of 3.43, indicating it is undervalued compared to its earnings potential. However, the main risk is the insider selling activity, which has increased by 145.95% over the last month, indicating potential concerns among insiders about the company's future performance.

7 analysts cover COLL: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 56.75.